JP2022525121A5 - - Google Patents

Info

Publication number
JP2022525121A5
JP2022525121A5 JP2021555034A JP2021555034A JP2022525121A5 JP 2022525121 A5 JP2022525121 A5 JP 2022525121A5 JP 2021555034 A JP2021555034 A JP 2021555034A JP 2021555034 A JP2021555034 A JP 2021555034A JP 2022525121 A5 JP2022525121 A5 JP 2022525121A5
Authority
JP
Japan
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
compound according
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021555034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525121A (ja
Filing date
Publication date
Priority claimed from GBGB1902490.0A external-priority patent/GB201902490D0/en
Application filed filed Critical
Publication of JP2022525121A publication Critical patent/JP2022525121A/ja
Publication of JP2022525121A5 publication Critical patent/JP2022525121A5/ja
Pending legal-status Critical Current

Links

JP2021555034A 2019-02-25 2020-02-17 Paskの阻害剤としてのピラゾロピリジン誘導体 Pending JP2022525121A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1902490.0 2019-02-25
GBGB1902490.0A GB201902490D0 (en) 2019-02-25 2019-02-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
PCT/EP2020/054122 WO2020173739A1 (en) 2019-02-25 2020-02-17 Pyrazolopyridine derivatives as inhibitors of pask

Publications (2)

Publication Number Publication Date
JP2022525121A JP2022525121A (ja) 2022-05-11
JP2022525121A5 true JP2022525121A5 (https=) 2023-02-20

Family

ID=65998935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021555034A Pending JP2022525121A (ja) 2019-02-25 2020-02-17 Paskの阻害剤としてのピラゾロピリジン誘導体

Country Status (19)

Country Link
US (1) US20220144823A1 (https=)
EP (1) EP3931191B1 (https=)
JP (1) JP2022525121A (https=)
KR (1) KR20210134001A (https=)
CN (1) CN113474344A (https=)
AR (1) AR124749A1 (https=)
AU (1) AU2020229041A1 (https=)
BR (1) BR112021016642A2 (https=)
CA (1) CA3130154A1 (https=)
CO (1) CO2021010485A2 (https=)
ES (1) ES2963409T3 (https=)
GB (1) GB201902490D0 (https=)
IL (1) IL285751A (https=)
MA (1) MA55074A (https=)
MX (1) MX2021010093A (https=)
PH (1) PH12021552032A1 (https=)
SG (1) SG11202109157TA (https=)
TW (1) TW202045505A (https=)
WO (1) WO2020173739A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022070288A1 (ja) * 2020-09-30 2022-04-07 旭化成ファーマ株式会社 含窒素二環化合物
WO2025143152A1 (ja) * 2023-12-27 2025-07-03 全薬工業株式会社 チアゾリル-ピラゾロ[1,5-a]ピリジン化合物、およびそのMYLK4阻害剤としての使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
JP2011530511A (ja) * 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
WO2010090716A1 (en) * 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US10392389B2 (en) * 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
CA2969265A1 (en) * 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use
EP3615538B1 (en) * 2017-04-27 2024-02-07 The Brigham and Women's Hospital, Inc. Novel alk2 inhibitors and methods for inhibiting bmp signaling

Similar Documents

Publication Publication Date Title
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2022525121A5 (https=)
JP5765739B2 (ja) ロスバスタチンラクトールの薬物としての使用
IL272115B (en) An aryl-phosphorus-oxygen compound as an egfr kinase inhibitor
JP7209897B2 (ja) Crbnタンパク質モジュレーターとしての二環式化合物
BG61118B2 (bg) Заместени бета-лактамни съединения,приложими като хипохолестеролемични агенти и метод за получаването им
JP2022023958A5 (https=)
JP2006515858A5 (https=)
JP2021522206A5 (https=)
JP2011037841A5 (https=)
JPH09511212A (ja) Δ▲上6▼,▲上7▼−タキソール類の抗悪性腫瘍的使用およびそれらを含む医薬組成物
JP2008526724A5 (https=)
JP2013518881A5 (https=)
JP2004506718A5 (https=)
JP2009537469A5 (https=)
JP2010510999A5 (https=)
TWI728017B (zh) 異吲哚化合物、包含其之醫藥組成物及其用途
CA2143744A1 (en) Diaryl piperazinoacetamide compounds as antimuscarinic agents
JP2024540164A5 (https=)
JP2006523698A5 (https=)
WO2001062708A1 (fr) Derives d'acide benzoique, procede de production desdits derives, et medicament contenant ces derives comme principe actif
RU2006111458A (ru) Фармацевтические композиции, содержащие малонамидные производные для уменьшения продукции кожного сала
RS50539B (sr) Postupak proizvodnje derivata 1,4-difenil-azetidinona
JP2006523626A5 (https=)
JP2007518798A5 (https=)